BioVenture VoiCes with Chris Garabedian

Jaksot

• 
  Episode 47: Ally Bridge's Andrew Lam 08.09.2026 1t 5min

  Andrew Lam describes his career journey that started with a Doctor of Pharmacy education before working in industry, the investment world, back in industry, and then settling at Ally Bridge. He discusses the successful investments Ally Bridge has made in biotech, including in technologies like radiopharmaceuticals and ADCs, and the concept of being a bridge to China innovation.
• 
  Episode 46: Catalys Pacific's BT Slingsby 24.08.2026 59min

  BT Slingsby describes his education and career abroad, which ultimately led him to found and manage the largest life sciences VC firm in Japan, Catalys Pacific. He describes the dual role of taking assets from Japan and building companies around them internationally., and also in-licensing assets approved elsewhere and doing the clinical work in Japan to get them approved there. Plus, the story of the GHIT Fund, which is meant to bring Japanese innovation to neglected diseases around the world.
• 
  Episode 45: Catalio Capital Management's George Petrocheilos 10.08.2026 1t 9min

  George Petrocheilos describes going to school at Hopkins and the relationships formed there that would ultimately lead down the road to specializing in healthcare investing. He discusses starting in life sciences investing at Camden Partners, and then co-founding Catalio. Over a short period of time, keys to success have been empowering academics and entrepreneurs and expanding into multiple strategies.
• 
  Episode 44: BainCapital's Adam Koppel 27.07.2026 1t 12min

  Adam Koppel describes his career path, which included a stop at McKinsey, Biogen, and twice at Bain (where he is now). He descrbies the private equity model they have been on the leading edge of, and his take on where we are in the biotech cycle. Plus, the critical importance of mentors.
• 
  Episode 43: Lightstone Venture's Mike Carusi 13.07.2026 1t 7min

  Mike Carusi describes his early life and career, how gaining an appreciation for sales made an impression on him early on, and his philosophy of investing in medical devices - and the similarities and differences between that and investing in therapeutics.
• 
  Episode 42: Nextech's Thilo Schroeder 15.06.2026 1t 5min

  Having been an early investor in many recent successes such as Revolution Medicines, Peloton, and Parabilis Medicines, he describes his investment philosophy and focus on precision oncology companies. Plus, his early life, getting hands on experience in biotech at Micromet, and learning from some of the top investors and scientific advisors in the industry.
• 
  Episode 41: Forbion's Nanna Lüneborg 01.06.2026 1t 2min

  Nanna Luneborg discusses hear career and joining Forbion. She describes the firm's investment approach, and her experience with everything from seed, to private, and to public investing in life sciences. Plus, thoughts on China and AI in biotech.
• 
  Episode 40: GV's Krishna Yeshwant 18.05.2026 1t 19min

  He describes his well-rounded background of studying and working in both software in Silicon Valley and Medicine in Boston, and the start of GV. He describes a conservative start to investing at GV, but also today how Alphabet's scale and cash gives them the ability to ride cycles and make concentrated bets on companies the team has conviction on.
• 
  Episode 39: SV Health Investors' Kate Bingham 04.05.2026 1t 12min

  Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more.
• 
  Episode 38: Deerfield Management's Jason Fuller 20.04.2026 1t 5min

  He discusses his education and joining the Langer Lab at MIT, early experiences in venture, including at Third Rock and NEA, and gaining operational experience at Jounce before joining Deerfield. Plus, areas that interest him today and how he thinks about AI.
• 
  Episode 37: SR One's Simeon George 23.03.2026 1t 6min

  Simeon George discusses his early days at SR One while it was part of GSK, and the transition to making the firm independent in 2020. Plus, the importance of peer-to-peer collaboration, and his how he thinks about investing in different indications and modalities.
• 
  Episode 36: Sofinnova Invetments' Jim Healy 09.03.2026 1t 1min

  He discusses learnings from his decades in venture at Sofinnova Investments including 'products vs platform', therapeutics areas of interest, modalities, and how he utilizes board seats and thinks about management teams.
• 
  Episode 35: INITIATE Ventures' Jessica Owens 23.02.2026 1t 9min

  Jessica Owens discusses the many experiences she has had in her career, including working on the venture side at Kleiner Perkins and Versant Ventures and on the operating side at Genomic Health and Grail. She highlights the value of VCs being able to understand how operators like CEOs think, and describes the type of investing INITIATE focuses on.
• 
  Episode 34: General Atlantic's Brett Zbar 09.02.2026 1t 7min

  Brett Zbar describes his early career, including working at Aisling Capital and Foresight Capital, and now managing the healthcare strategy at General Atlantic. He describes how he sees the difference between private equity and venture capital, and discusses which themes in biotech and healthcare appeal to him today.
• 
  Episode 33: Pappas Capital's Art Pappas 26.01.2026 58min

  Art Pappas describes his early career, which involved numerous overseas posts for large companies, and how it let him to eventually found Pappas Capital. He discusses the various ways the firm invests, and how having corporates partners as LPs and co-investors has been a recipe for success.
• 
  Episode 32: ARCH Venture Partners' Bob Nelsen 11.01.2026 1t 15min

  While describing his early life in Washington and formative years at the University of Chicago that led to the founding of ARCH, he shares his thoughts on leadership, risk taking, changes he thinks are need to keep the United States competitive in life sciences, and his belief in AI's promise to transform our industry.
• 
  Episode 31: Polaris Partners' Amy Schulman 29.12.2025 1t 2min

  She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam.
• 
  Episode 30: F-Prime Capital Senior Managing Partner Stephen Knight 15.12.2025 1t

  He describes his early life and career experiences at Bell Labs, consulting work, and EPIX Pharmaceuticals before landing in his true interest, venture capital. Dr. Knight describes the foresight of Fidelity to focus on life sciences in its early days, and F-Prime's investing philosophy today.
• 
  Episode 29: Averin Managing Partner David Berry 01.12.2025 1t 19min

  He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology.
• 
  Episode 28: Hatteras Venture Partners' Clay Thorp 10.11.2025 1t

  Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders.